Clinical Trial Update: Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms [Phase 2]

View source ↗

Summary

Phase 2 long-term safety and efficacy study of MT-8554 for vasomotor symptoms in postmenopausal women has completed, with results posted in October 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Menopause
• Vasomotor Symptoms

Drugs mentioned

• MT-8554

Snippet

Sponsor: Tanabe Pharma America, Inc. | Conditions: Vasomotor Symptoms (VMS) | Phase 2 | Status: COMPLETED | Results posted: 2022-10-03